Cardiotrophin-1 (CT-1) is a cytokine of the interleukin-6 superfamily which is up-regulated in cardiac diseases, in part via hypoxia-dependent mechanisms. However, no evidence for a direct regulation of CT-1 gene (CTF1) promoter by hypoxia inducible factor-1 (HIF-1) has been provided.
Introduction
Cardiac muscle cell survival plays a critical role in maintaining the correct function of the heart and possibly in cardiac development. Adult cardiomyocytes are thought to be terminally differentiated and therefore have lost their proliferative capacity. One of the mechanisms that cardiomyocytes employ to protect themselves from deleterious stimuli is the release of survival cytokines capable of promoting cytoprotection in an autocrine/paracrine manner. 1 -3 Cardiotrophin-1 (CT-1) is a member of the interleukin-6 family with hypertrophic properties in neonatal and adult cardiomyocytes. 4 -6 Additionally, CT-1 shows cytoprotective effects in neonatal cardiomyocytes subjected to serum deprivation, 7, 8 heat shock and lethal ischaemia, 9 and ischaemia-reperfusion. 10 In adult cardiomyocytes, CT-1 exerts a protective function in response to death stimuli such as angiotensin II and hydrogen peroxide 11 and to ischaemia-reperfusion. 12 Cardioprotective properties of CT-1 under stress conditions suggest that it may be up-regulated during cardiac diseases that are † P.A.R. and G.S.J. contributed equally to this study.
characterized by an environment of reduced oxygen availability, inflammation, and oxidative stress. Indeed, circulating levels of CT-1 are elevated in pathological conditions associated with ischaemia, including unstable angina pectoris, 13 acute myocardial infarction (MI), 14, 15 hypertensive heart disease, 16, 17 and heart failure. 18, 19 Interestingly, CT-1 expression is up-regulated by hypoxic stress in embryonic and adult cardiomyocytes, 20 although the underlying molecular mechanisms remain unclear.
A major transcription factor involved in the molecular effects triggered by hypoxia is hypoxia inducible factor-1 (HIF-1). HIF-1 consists of an oxygen labile alpha subunit (HIF-1a) and an oxygen inert beta subunit (HIF-1b). 21 Under normoxic conditions, the HIF-1a protein is readily degraded via the ubiquitin-mediated degradation pathway. In hypoxia, the stabilized HIF-1a protein dimerizes with HIF-1b, and initiate transcription of target genes containing hypoxia response elements (HRE). 22 Studies using HIF-1a-deficient (HIF-1a 2/2 ) embryonic stem cells (ESCs) suggest that HIF-1 is involved in the regulation of CT-1 by hypoxia. 23 Additionally, exogenous expression of HIF-1a promotes cardiac differentiation of ESCs and up-regulates the expression of cardiogenic factors, including CT-1. 24 Collectively, these studies suggest that the HIF-1 pathway is involved in the regulation of CT-1 expression in cultured ESCs. Nevertheless, currently no evidence for a direct regulation of the promoter of the CTF1, the human gene of CT-1, has been provided. In order to test whether the CT-1 promoter possesses functional HREs, we characterized the promoter region of CTF1 in a model of adult cardiomyocytes (HL-1 cells), 25 and evaluated its activity under hypoxic conditions. The results of this study may further clarify the molecular mechanisms involved in the response of cardiomyocytes to hypoxic conditions, which may mediate cardioprotection in the embryonic and adult heart.
Methods
Please see online Supplementary material for detailed methods.
Cell culture
HL-1 cardiomyocytes, an immortalized cell line derived from mouse atria cardiac myocytes, 25 were cultured in the Claycomb medium (Sigma) supplemented with 10% foetal bovine serum (FBS), 100 U/mL penicillin, 0.1 mg/mL streptomycin, 0.1 mM norepinephrine, and 2 mM L-glutamine.
Prior to experiments, cells were arrested overnight in the Claycomb medium supplemented with antibiotics, norepinephrine, L-glutamine, and 0.3% FBS. Then, cells were exposed to hypoxia (1% O 2 , 5% CO 2 , balanced with N 2 ) in a hypoxic incubator (MCO18A; Sanyo). For certain experiments, cells were treated with inhibitors for 30 min before the hypoxic stimulus. The inhibitors used were lercanidipine (a calcium channel blocker of the dihydropyridine class; 1 mM), 1,2-bis(2-aminophenoxy) ethane-N,N,N ′ ,N ′ -tetraacetic acid tetrakis acetoxymethyl ester (BAPTA-AM, a Ca 2+ chelator; 15 mM; Sigma), wortmannin [a phosphatidylinositol-3 kinase (PI3K)/Akt inhibitor; 1 mM; Sigma], and rapamycin [a mammalian target of rapamycin (mTOR) inhibitor; 100 nM; Sigma].
HEK-293 cells, were cultured in 378C with 5% CO 2 using DMEM supplemented with 10% FBS and antibiotics. These cells were used for co-transfection and ChIP experiments.
Animal procedures
All procedures followed in the study were reviewed and approved by the Animal Care and Experimentation Committee of the Research Center. The investigation conforms to the Guide for the care and Use of laboratory Animals published by the US National Institutes of Health (NIH Publication No. 85-23, revised 1996) . Male C57BL/6 mice (2 months old; n ¼ 32; Charles River) were exposed to continuous hypoxia (n ¼ 16) or room air [Control group (Normoxia); n ¼ 16]. Hypoxia exposure was done by a gas delivery system, using a hypoxic gas mixture (10% O 2 , balanced with N 2 ) (Abelló Linde). 26 Mice were kept under hypoxia or normoxia for 24 h (n ¼ 8) or 48 h (n ¼ 8). Mice were intraperitoneally anesthetized with ketamine (150 mg/kg; Merial Laboratories) and medetomidine (1 mg/kg; Divasa-Farmavic). Tissues were frozen in liquid nitrogen and stored at 2808C for subsequent RNA extraction.
Real-time PCR
Total RNA from HL-1 and HEK-293 cells and mouse tissues was isolated with RNAeasy kit (Qiagen GmbH). cDNA was prepared by reverse transcription of 1 mg RNA with the SuperScript VILO cDNA Synthesis kit (Invitrogen). mRNA levels were quantified by real-time PCR using TaqMan TM Gene Expression probes (Applied Biosystems) for CT-1 (Mm00432772_m1 and Hs00173498_m1 for mouse and human CT-1, respectively) and for 18S rRNA (4319413E). Real-time PCR data were analysed for relative gene expression normalizing to 18S rRNA levels.
Western blot analysis
Protein was extracted from HL-1 or HEK-293 cells with RIPA lysis buffer (50 mM Tris pH ¼ 8, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, and 0.1% SDS) containing the protease inhibitor cocktail Complete (Roche). Western blot analysis was performed as previously described. 27 Membranes were incubated with antibodies against Akt phosphorylated in Ser 473 and total Akt (Cell Signaling), HIF-1a and HIF-1b (Santa Cruz), and CT-1 (R&D Systems). Bound antibody was detected using the appropriate horseradish peroxidase-conjugated antibody and the ECL system (Amersham). The equal loading of protein in each lane was verified by reblotting the membranes with an anti-b-actin antibody (Santa Cruz).
siRNA methodological approaches
Predesigned small-interfering RNA targeting HIF-1a (Silencer w Select siRNAs s67530) or negative-control siRNA (Silencer w Select Negative Control#1siRNA) from Applied Biosystems were used in knockdown experiments. HL-1 cells were transfected with siRNAs using Lipofectamine-RNAiMAX (Invitrogen), as discussed previously. 27 After transfection, cells were kept in complete medium for 24 h, arrested, and then exposed to hypoxia for 16 h.
In additional experiments, HL-1 cells were infected with siRNA lentiviral particles, siCT-1 (CT-1 shRNA-mouse Lentiviral Particles, sc-39328-V) or siControl (Control shRNA Lentiviral Particles, sc-108080) from Santa Cruz, grown in complete medium for 48 h and selected with puromycin. These selected knocked-down cells were arrested, exposed to hypoxia for 16 h, and used to study apoptosis.
Constructs of CT-1 promoter
A 2822 bp DNA sequence upstream of the exon 1 of the human CT-1 gene was amplified by PCR, and was cloned into the pGL3-Basic luciferase reporter vector (Promega) (hCT1-2822 construct). The amplification product contained 41 nt downstream from the ATG codon and 2781 nt upstream from the same codon. Several constructs of the putative promoter region were generated from hCT1-2822 (see Supplementary material online, Figure S1 ). The putative HRE sites present in the shortest CT-1 construct (hCT1-204) were mutated using the QuickChange SiteDirected Mutagenesis kit (Stratagene).
Transient transfection
For luciferase assay experiments, HL-1 cells were transfected with the luciferase reporter plasmids using Lipofectamine 2000 (Invitrogen).
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After transfection, cells were washed and arrested for 16 h, and then exposed to hypoxia for 16 h. Luciferase activity was measured using the Dual-Luciferase Reporter Assay System (Promega).
In some experiments, HL-1 cells were transfected with pCDNA3-Hif-1a kindly provided by Dr E. Huang (Department of Health & Human Services, NIH, Bethesda) in normoxia. After 24 h from transfection, mRNA levels of CT-1 were determined.
Co-transfection assays were performed on HEK-293 cells in normoxic conditions; the CT-1 promoter constructs were co-transfected with the pCDNA3-HIF-1a or the control pCDNA3 plasmid, and luciferase was determined. 
Annexin

Caspase 3/7 activities
Caspase 3 and 7 play a key effector role in apoptosis. HL-1 cells infected with siRNA lentiviral particles (siCT1 or siControl) were plated in whitewalled 96-well plates. Cells were arrested and exposed to hypoxia for 16 h. Finally, cells were incubated with Caspase-Glo w 3/7 Reagent (Promega) according to the manufacturer's recommendations.
HIF-1a decoy experiments
HL-1 cells were transiently transfected as described above with the hCT1-204 construct and 100-fold molar excess of double-stranded oligodeoxynucleotide containing consensus HRE or a control HRE-mutated oligodeoxynucleotide. Transfected cells were exposed to hypoxia for 16 h and luciferase activity was measured.
Electrophoretic mobility shift assays
Nuclear extracts were isolated from HL-1 cells under normoxia or exposed to hypoxia for 4 h, and electrophoretic shift assay was performed according to a conventional protocol.
ChIP assay
ChIP assays were performed in HEK-293 by using the HIF-1a ExactaChIP TM kit (R&D Systems). 28 
Statistical analysis
Data are expressed as mean + standard error of the means (SEM). Statistical differences between mean values were tested by one-way ANOVA once normality was demonstrated (Shapiro -Wilks test), and a Scheffé post hoc test was used to examine differences between groups when significance was achieved; otherwise a Kruskal-Wallis followed by Mann-Whitney U-test were used (adjusting the a-level by Bonferroni inequality).
Results
Hypoxia induces CT-1 expression
Hypoxia up-regulated CT-1 mRNA in a time-dependent manner. CT-1 expression was significantly higher at 6 h (two-fold) in cells maintained under hypoxia than in normoxic cells, and reached a peak at 24 h of hypoxia ( Figure 1A) . Accordingly, protein levels of CT-1 were increased at 16 h of hypoxia (see Supplementary material online, Figure S2 ). We also tested whether hypoxia up-regulates CT-1 in vivo in different animal tissues. Systemic hypoxia significantly induced CT-1 expression in the heart (at 24 and 48 h) and in the brain (at 48 h) ( Figure 1B) . A similar trend (but not statistically significant) was observed in the kidney.
In transient transfection experiments in HL-1 cells, hypoxia increased the transcriptional activity of a luciferase reporter plasmid containing 2822 bp of the CT-1 promoter (hCT1-2822) ( Figure 1C ). This effect was also observed for shorter CT-1 promoter constructs, including the shortest one (hCT1-204). These results support that hypoxia-induced CT-1 up-regulation may be due to an increased transcriptional activity of the CT-1 gene, and suggest that HREs may be located proximal to the ATG codon in the promoter of the gene.
Signalling pathways involved in CT-1 induction by hypoxia in cardiomyocytes
Inhibition of calcium mobilization (by BAPTA-AM, a calcium chelator, or by lercanidipine, a calcium channel blocker) significantly reduced hypoxia-induced CT-1 mRNA levels ( Figure 2A) . Hypoxia-induced CT-1 mRNA upregulation was also prevented by inhibiting the PI3K/Akt axis (with wortmannin) and its downstream target mTOR (with rapamycin). Accordingly, these inhibitors also prevented the increased luciferase activity induced by hypoxia in the hCT1-2822 construct ( Figure 2B) .
Inhibition with BAPTA-AM significantly reduced the hypoxia-induced Akt activation (phosphorylated Ser-473) ( Figure 2C ), thus suggesting a relevant role of calcium mobilization in the activation of the PI3K/Akt axis. Wortmannin also prevented activation of Akt induced by hypoxia.
HIF-1a is involved in the up-regulation of CT-1 by hypoxia
Hypoxia up-regulated HIF-1a protein levels in a time-dependent manner ( Figure 3A) . No changes were observed in the levels of the constitutive isoform (HIF-1b). To test whether HIF-1a induction underlies the up-regulation of CT-1 by hypoxia, HL-1 cells were transfected with the siRNA against HIF-1a. HIF-1a silencing prevented both the hypoxia-induced up-regulation of HIF-1a protein levels (see Supplementary material online, Figure S3 ) and the downstream induction of CT-1 expression ( Figure 3B) . Consistent with this, HIF-1a over-expression up-regulated CT-1 in normoxic HL-1 cells HIF1 upregulates cardiotrophin-1 in hypoxia ( Figure 3C ). Inhibitors that prevented the induction of CT-1 by hypoxia also prevented the increase of HIF-1a induced by hypoxia in HL-1 cells ( Figure 3D ).
Hypoxia induces CT-1 promoter activity through functional HREs
In human HEK-293 cells, HIF-1a over-expression increased the transcriptional activity of reporter plasmids containing serial deletions of the CTF1 promoter ( Figure 4A) . By in silico analysis, we identified several putative HREs along the CT-1 promoter. Two of them were located within the shortest promoter construct (hCT1-204), which retained full responsiveness to hypoxia and to HIF-1a overexpression. In decoy experiments, the HIF-1a oligodeoxynucleotide significantly reduced the luciferase level directed by the hCT1-204 construct in response to hypoxia, unlike the mutated HIF-1a oligodeoxynucleotide ( Figure 4B) .
The two HREs are placed 30 and 73 bp upstream from the ATG codon. The simultaneous mutation of both HREs was necessary to completely abolish the hypoxia-induced CT-1 promoter activity ( Figure 5A and B) . EMSA analyses confirmed that HIF-1a specifically binds to these HRE sites. Indeed, the addition of an antibody against HIF-1a completely prevented the binding of nuclear extract from hypoxic cells to both HRE-1 and HRE-2 ( Figure 5C ). Finally, ChIP assays in human cells confirm that HIF-1 directly binds to these putative HRE sites present in CTF1 promoter (see Supplementary material online, Figure S4 ). Collectively, these experiments demonstrate that HIF-1 specifically binds to two HRE motifs in the human CT-1 promoter, resulting in the activation of CT-1 transcription.
CT-1 knock-down potentiates hypoxia-induced apoptosis in cardiomyocytes
Silencing of CT-1 by lentiviral particles efficiently decreased CT-1 mRNA expression compared with cells transducted with control lentiviral particles (see Supplementary material online, Figure S5) . By flow cytometry, we found that silencing of CT-1 significantly increased apoptosis in HL-1 cells exposed to hypoxia ( Figure 6A and B) . Silencing of CT-1 also increased apoptosis in cells under normoxia. Similarly, and by fluorescent microscopy, we observed an increase in the binding of annexin V by CT-1 knocked-down HL-1 cells under hypoxia ( Figure 6C) . Likewise, caspase 3/7 activity was higher in CT-1 knocked-down HL-1 cells than in control cells both in conditions of normoxia and hypoxia ( Figure 6D) . Therefore, CT-1 seems to be involved in the cell survival response to hypoxia.
Discussion
The main findings of this study are as follows: (i) hypoxia increases CT-1 expression both in vitro (in the murine cardiomyocyte cell line HL-1) and in vivo (in the hearts of mice exposed to systemic hypoxia); (ii) hypoxia-induced CT-1 expression is mediated by a signalling pathway that involves Ca 2+ , PI3K/Akt/mTOR and HIF-1;
(iii) the transcription factor HIF-1 is directly involved in the up-regulation of CT-1 by hypoxia through two HREs present in the promoter of the CTF-1 gene, and (iv) the increased CT-1 expression protects HL-1 cardiomyocytes from hypoxia-induced apoptosis. Oxygen availability plays a key role in several cardiac conditions, including ischaemic heart disease, congestive heart failure, and hypertensive heart disease. Interestingly, these conditions have been recently associated with increased levels of CT-1. 13 -19 In the present study, we found that hypoxia increases CT-1 expression in the murine adult cardiomyocyte cell line HL-1, mainly through an increase in the transcriptional rate, confirming and extending previous studies in cardiomyocytes 20 and in embryoid bodies. 23 The HL-1 cell line constitutes an attractive model for hypoxia-induced studies due to the presence of specific hypoxic inducible genes. In fact, the response of these HL-1 cells to hypoxia is similar to the expected response of rodent cardiomyocytes. 29 Besides, our in vivo findings
showing that CT-1 expression is enhanced in the hearts from mice exposed to hypoxia support the validity of the HL-1 cell model. The increment of cardiac CT-1 expression was observed within 24 h, in agreement with previous studies in experimental models of MI that reported significant up-regulation of CT-1 24 h after intervention. 2, 14 CT-1 induction in the heart was more sensitive to systemic hypoxia than other tissues, such as the brain or kidney, according with the high susceptibility to oxygen deprivation of this obligate aerobic organ. These results support the role of hypoxia as a driving force regulating cardiac CT-1 expression in vivo, although under our experimental conditions CT-1 increase was discreet. Further studies should be performed in order to elucidate the entire mechanism by which CT-1 is upregulated in vivo.
The signalling pathways implicated in the molecular regulation of CT-1 by hypoxia are still not well known. The implication of HIF-1 in the up-regulation of CT-1 by hypoxia has been suggested by Ateghang et al. 23 who showed that in ESCs a HIF-1a inhibitor (2-methoxyestradiol) abolished CT-1 expression induced by 'chemical' hypoxia (using CoCl 2 ). In the same study, the authors showed that in developing embryoid bodies derived from a HIF-1a-deficient ESC line, hypoxia was unable to up-regulate CT-1. 23 On the other hand, the over-expression of HIF-1a into ESCs up-regulated CT-1. 24 In the present study, we report that hypoxia increased HIF-1a protein levels in HL-1 cells, confirming previous data. 30 We have found that hypoxia elevates CT-1 mRNA levels via a HIF-1a-dependent mechanism, supported by the data showing that hypoxia-induced CT-1 expression was inhibited by the HIF-1a silencing, while over-expression of HIF-1a up-regulated CT-1 in HL-1 Several signalling pathways are involved in hypoxia-induced HIF-1a activation. Using inhibitors of individual signalling pathways, we found that hypoxia-induced CT-1 expression may be dependent on calcium mobilization, PI3K, and mTOR. Our findings suggest that activation of PI3K/Akt, a signalling pathway involved in the upregulation of HIF-1a and survival of cells, 31 intracellular calcium may play a key role, according to a previous study. 32 Given the tightly regulation of mitochondrial respiration by matrix calcium concentration, the involvement of calcium in cell signalling under conditions of low oxygen availability (hypoxia) further emphasize the role of the interplay mitochondria-sarcoplasmic reticulum under pathophysiological conditions. 33 Collectively, these findings suggest that all these signalling molecules co-ordinately participate in a common pathway that triggers CT-1 upregulation (see Supplementary material online, Figure  S6 ). In agreement with these findings, chemical hypoxia induced by CoCl 2 has been shown to promote CT-1 up-regulation also through the activation of PI3K signalling. 23 Further experiments should be performed in order to underline the relevance of these findings.
Our findings in CT-1-knocked-down HL-1 cells suggest that the CT-1 up-regulation induced by hypoxia might protect cells from apoptosis. Furthermore, the reduction in CT-1 expression using lentiviral particles increased apoptosis in both normoxia and hypoxia compared with controls. These data are in agreement with other studies showing that CT-1 treatment decreased the apoptosis of embryonic, neonatal, and adult cardiomyocytes. 12, 34, 35 In this regard, CT-1 administration in rats has been shown to decrease cell death in the intact perfused heart exposed to ischaemia. 12 Such protective effect has also been reported in atrial appendages of adult heart from patients exposed to ischaemic injury. 36 Although it is commonly assumed that HIF-1a stabilization/ up-regulation occurs in response to hypoxic conditions, several studies have recently demonstrated an up-regulation, stabilization, and activation of HIF-1a in a normoxic background. It is worth-noting that various humoural factors which play an important role in the pathophysiology of cardiac disorders such as growth factors (plateletderived growth factor, insulin-like growth factor-2), 37 , and maintained under normoxia (white bars) or exposed to hypoxia (black bars). Similar results were obtained when wild-type and mutated constructs were co-transfected with a control vector (pCDNA3; white bars) or a HIF-1a expression vector (pCDNA3-HIF-1a; grey bars). n ¼ 6, in triplicate. *P , 0.05 vs. control condition. (C) EMSA analysis of HIF-1a DNAbinding activity. Nuclear extracts from HL-1 cells exposed to normoxia or hypoxia were incubated with wild-type or mutated 32 P-labelled doublestranded oligonucleotides from the CT-1 promoter regions containing the HRE1 or HRE2 sites. In some experiments, co-incubation with 200-fold molar excess of non-radiolabelled oligonucleotides or anti-HIF-1a was performed.
HIF1 upregulates cardiotrophin-1 in hypoxia levels of these factors could potentially activate HIF-1a and eventually induce CT-1 in a chronic way. In summary, we found that in adult murine cardiomyocytes, HIF-1a is directly involved in the transcriptional up-regulation of CTF1 by hypoxia. This CT-1 activation by hypoxia may inhibit apoptosis, suggesting a protective role of CT-1 in response to acute hypoxia in vivo.
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